These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 21406645)

  • 1. Leukemic stem cell gene expression signature and clinical outcomes in acute myeloid leukemia.
    Masuda S
    JAMA; 2011 Mar; 305(11):1094; author reply 1094-5. PubMed ID: 21406645
    [No Abstract]   [Full Text] [Related]  

  • 2. An extracellular matrix signature in leukemia precursor cells and acute myeloid leukemia.
    Izzi V; Lakkala J; Devarajan R; Ruotsalainen H; Savolainen ER; Koistinen P; Heljasvaara R; Pihlajaniemi T
    Haematologica; 2017 Jul; 102(7):e245-e248. PubMed ID: 28411251
    [No Abstract]   [Full Text] [Related]  

  • 3. Leukemia stemness signatures step toward the clinic.
    Becker MW; Jordan CT
    Cell Stem Cell; 2011 Sep; 9(3):185-6. PubMed ID: 21885015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of a murine leukaemia stem cell gene signature based on nucleostemin promoter activity with prognosis of acute myeloid leukaemia in patients.
    Ali MA; Naka K; Yoshida A; Fuse K; Kasada A; Hoshii T; Tadokoro Y; Ueno M; Ohta K; Kobayashi M; Takahashi C; Hirao A
    Biochem Biophys Res Commun; 2014 Jul; 450(1):837-43. PubMed ID: 24960197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bringing a Leukemic Stem Cell Gene Signature into Clinics: Are We There Yet?
    Richard-Carpentier G; Sauvageau G
    Cell Stem Cell; 2017 Mar; 20(3):300-301. PubMed ID: 28257710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acute myeloid leukemia].
    Yamaguchi H
    Rinsho Ketsueki; 2013 Jan; 54(1):39-48. PubMed ID: 23391646
    [No Abstract]   [Full Text] [Related]  

  • 7. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design.
    Wouters R; Cucchi D; Kaspers GJ; Schuurhuis GJ; Cloos J
    Expert Rev Hematol; 2014 Dec; 7(6):791-805. PubMed ID: 25242511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML.
    de Jonge HJ; Woolthuis CM; Vos AZ; Mulder A; van den Berg E; Kluin PM; van der Weide K; de Bont ES; Huls G; Vellenga E; Schuringa JJ
    Leukemia; 2011 Dec; 25(12):1825-33. PubMed ID: 21760593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current clinical trials using new targeted therapies for myeloid leukemia and the research trends].
    Ishizawa J; Saya H
    Nihon Rinsho; 2009 Oct; 67(10):1932-7. PubMed ID: 19860193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells.
    Hatfield KJ; Reikvam H; Bruserud Ø
    Expert Opin Ther Targets; 2014 Nov; 18(11):1237-51. PubMed ID: 25200484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Entinostat prevents leukemia maintenance in a collaborating oncogene-dependent model of cytogenetically normal acute myeloid leukemia.
    Ramsey JM; Kettyle LM; Sharpe DJ; Mulgrew NM; Dickson GJ; Bijl JJ; Austin P; Mayotte N; Cellot S; Lappin TR; Zhang SD; Mills KI; Krosl J; Sauvageau G; Thompson A
    Stem Cells; 2013 Jul; 31(7):1434-45. PubMed ID: 23592435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New clinical evidence and drugs].
    Kobayashi Y
    Rinsho Ketsueki; 2013 Oct; 54(10):1660-70. PubMed ID: 24064815
    [No Abstract]   [Full Text] [Related]  

  • 14. [Acute myeloid leukemia: from risk-adapted to genotype-specific therapy].
    Kayser S; Schlenk RF
    Dtsch Med Wochenschr; 2011 Aug; 136(31-32):1577-80. PubMed ID: 21809245
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
    Pelosi E; Castelli G; Testa U
    Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neoplastic mastocytosis evolving from a poor prognosis acute myeloid leukemia].
    Chen-Liang TH; Jerez A; Florensa L; Ortuño FJ
    Med Clin (Barc); 2015 Jun; 144(12):571-2. PubMed ID: 25249393
    [No Abstract]   [Full Text] [Related]  

  • 17. Early gene expression of acute myeloid leukemia in response to chemotherapy.
    Anensen N; Øyan AM; Huseby S; Kalland KH; Bruserud Ø; Gjertsen BT
    Expert Rev Anticancer Ther; 2007 May; 7(5):741-51. PubMed ID: 17492937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential chemosensitivity of leukemic cells in the myeloid and lymphoid phases of stem cell leukemia (a case report).
    Mihál V; Hajdúch M; Dusek J; Jarosová M; Weigl E; Pikalová Z; Indrák K; Safárová M; Janostáková A
    Neoplasma; 1997; 44(2):133-6. PubMed ID: 9201294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [AML stem cell].
    Miyamoto T
    Rinsho Ketsueki; 2013 Oct; 54(10):1643-50. PubMed ID: 24064813
    [No Abstract]   [Full Text] [Related]  

  • 20. Elevated HIF-1α expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy.
    Matsunaga T; Imataki O; Torii E; Kameda T; Shide K; Shimoda H; Kamiunten A; Sekine M; Taniguchi Y; Yamamoto S; Hidaka T; Katayose K; Kubuki Y; Dobashi H; Bandoh S; Ohnishi H; Fukai F; Shimoda K
    Leuk Res; 2012 Jun; 36(6):e122-4. PubMed ID: 22444690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.